mRNA technologies are the next big therapeutic modality with RNA based vaccines looking to have a major impact due to their shorter manufacturing times and greater effectiveness. This proves to be of more importance in this time of COVID-19, with the necessity to get an effective vaccine to the market at speed while ensuring regulatory and quality compliance.
As mRNA vaccines move through the clinic, we need to source cGMP facilities to safely bring these products to the market. We are working with clients today to bring these revolutionary medicines to the world. Contact us to discuss how we can support your teams to develop capacity for your clinical and commercial pipeline.
Tell us about your project
and discover how DPS can help you today